Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
NOVATO, Calif., May 10, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 16, 2017 at 3:00 pm PT in Las Vegas, NV.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
